top of page
Search

Cell-free biotech could drive COVID-19 therapeutics

  • Writer: DLRG
    DLRG
  • Apr 12, 2020
  • 1 min read

Updated: Feb 7, 2021

Platform could produce new antiviral drugs more than 10 times faster

A biomanufacturing company spun out of the DLRG is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University.


To learn more, see the stories:


 
 
 

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.

Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

© 2018 by DLRG. Proudly created with Wix.com

bottom of page